Scientists Criticize Drug War at Psychedelics Event Hosted by Federal Health Agency

May 3, 2021 14:05:23

Last week, a federal health agency begun a speaker series that will be focused on reviewing the science behind psilocybin mushrooms and the therapeutic potential they possess. Experts who aired their views at the inaugural event claimed that federal drug regulations undermined the scientific community’s research objectives and weren’t in line with what the voters wanted.

The event is being hosted by the National Cancer Institute, under the National Institutes of Health (“NIH”). The institute notes that it has some clinical trials looking into the use of psilocybin as a treatment of cancer-related depression, with others exploring the psychedelic’s potential application as a treatment of various psychiatric disorders. This, the institution adds, is despite the fact that federal laws classify the substance as a Schedule 1 substance.

The National Cancer Institute also revealed that it was organizing a Psilocybin Research speaker series, which begin  occur over the coming weeks.

The series has two main objectives: first, to provide evidence-based and time-sensitive scientific information of this substance, using expert speakers from the government, academia and scientific communities; and second, to identify research opportunities and gaps as well as evaluating the current state of the science.

The initial event featured Johns Hopkins University and UCLA professors leading various presentations, among them one on psilocybin use in end-of-life care.

UCLA’s Dr. Charles Grob discussed the need for better funding for psychedelic research as well as increased diversity among those who took part in the studies. Grob also stated that while measures of decriminalization continued being approved in various states across the country, it was still important that public education programs be introduced. These programs would focus on the safe use of psychedelics in states that decided to loosen criminal penalties or approve decriminalization laws.

Another professor, Johns Hopkins University’s Dr. Roland Griffiths, noted that the Schedule 1 classification of psilocybin made both preclinical and clinical research much more difficult to conduct. He explained that to work with a Schedule 1 compound, researchers had to obtain a DEA license and jump through various hoops, which may have discouraged some.

Psychedelic substances are gaining more attention around the country as a national movement calling for an end to the criminalization of substances that show considerable therapeutic potential grows.

Among the latest iterations of the national psychedelics reform movement, which has grown significantly since 2019 when Denver decriminalized psilocybin mushrooms, are those taking place in Washington D.C., Ann ArborSanta Cruz and Oakland, which have decriminalized the possession of fungi and plant-based psychedelics.

The fact that federal agencies in the United States are beginning to take a keen look at psychedelics is a possible source of encouragement to sector players such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) because it offers hope that a change in federal policy will one day be made, and regulatory impediments will be eased.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.